# RECOVAC Repeated Vaccination Study

> **NCT05030974** · PHASE4 · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 336 (actual)

## Conditions studied

- Covid19
- Kidney Diseases
- Vaccine Response Impaired
- SARS-CoV2 Infection

## Interventions

- **BIOLOGICAL:** mRNA-1273
- **BIOLOGICAL:** Ad26.COV2.S vaccine

## Key facts

- **NCT ID:** NCT05030974
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-21
- **Primary completion:** 2022-03-12
- **Final completion:** 2022-03-12
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2022-03-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05030974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05030974, "RECOVAC Repeated Vaccination Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05030974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*